Profitability
Weight: 15%
F
0
- 5yr Avg ROIC -34.4%
- Operating Margin Trend -88.61 pp/yr
SNDX
Syndax Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 27.6 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -290.3%
- 5yr Share-Count CAGR 13.6%
Growth Quality
Weight: 35%
D+
43
- 5yr Revenue CAGR 5.4%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
D+
44
- 5yr FCF Margin -442.6%
- 5yr FCF/NI Conversion 1.16x
Balance Sheet
Weight: 10%
F
0
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -7.45x
- Altman Z-Score -1.85
Stability
Weight: 5%
B+
77
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 2
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 added; 1 trimmed; 1 full exit.
- Holders
- 2
- Avg Δ position
- -14.0%
- New buys
- 0
- Full exits
- 1
- Greenblatt sold -100%
- Wood decreased -59%
- Cooperman increased +31%